The Influence of Plasma and Aqueous Cytokine Concentrations on the Efficacy of Intravitreal Ranibizumab for the Treatment of Diabetic Macular Oedema.
Phase of Trial: Phase IV
Latest Information Update: 20 Jan 2018
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Pharmacodynamics
- Acronyms DISCERN; DME Cytokine
- 11 Jan 2018 Status changed from active, no longer recruiting to completed.
- 02 Dec 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Sep 2015 New trial record